American College of Cardiology 74th Annual Scientific Session & Expo (ACC.25)

Chicago, Illinois, US 29 March 2025 - 31 March 2025

Rivaroxaban a game-changer for acute LV thrombus post-MI

15 May 2025 by

Patients who develop an acute thrombus in the left ventricle (LV) following myocardial infarction (MI) fare equally well when treated with rivaroxaban as they do with warfarin, as shown in the RIVAWAR study.

Rivaroxaban a game-changer for acute LV thrombus post-MI

15 May 2025

Fluid restriction good for chronic HF: Aye or nay?

14 May 2025 by

Allowing patients with chronic heart failure (HF) to drink as much fluid as they need appears to present no additional risks, including for hospitalization and death, as shown in the FRESH-UP study presented at ACC.25. This finding challenges the current US and EU recommendations to limit daily fluid intake to 1.5 L for this population.

Fluid restriction good for chronic HF: Aye or nay?

14 May 2025

Skin pigmentation affects pulse oximeter performance

27 Apr 2025 by

Findings from the EquiOx trial presented at ACC.25 underpin the influence of skin pigmentation in pulse oximetry.

Skin pigmentation affects pulse oximeter performance

27 Apr 2025

4F-PCC bests frozen plasma as factor replacement for cardiac surgery bleeds

26 Apr 2025 by

For physicians requiring coagulation factor replacement to control bleeding after CPB during surgery, 4F-PCC provides superior haemostatic efficacy over frozen plasma, along with some safety advantages, as shown in the FARES-II trial presented at ACC.25

4F-PCC bests frozen plasma as factor replacement for cardiac surgery bleeds

26 Apr 2025

Study affirms bentracimab potential for ticagrelor reversal in patients requiring surgery or with bleeding

21 Apr 2025 by

The first-in-class monoclonal antibody bentracimab effectively and safely reverses the antiplatelet effects of ticagrelor in patients with an indication for urgent or emergent surgery or with major bleeding in the single-arm phase III REVERSE-IT trial.

Study affirms bentracimab potential for ticagrelor reversal in patients requiring surgery or with bleeding

21 Apr 2025

Novel PCSK9 inhibitor for high cholesterol passes phase II trial

15 Apr 2025 by

A recent trial presented at ACC.25 has demonstrated the efficacy of AZD0780 in reducing low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia, with a favourable safety and tolerability profile.

Novel PCSK9 inhibitor for high cholesterol passes phase II trial

15 Apr 2025

Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?

15 Apr 2025 by

Long-term treatment with tirzepatide results in improved renal function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, regardless of the absence or presence of chronic kidney disease (CKD), according to a post hoc analysis of the SUMMIT trial presented at ACC.25.

Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?

15 Apr 2025

Oral semaglutide reduces CV risk in T2D patients

15 Apr 2025 by

Once-daily treatment with oral semaglutide, a GLP-1* receptor agonist, significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), according to the SOUL** trial presented at ACC.25.

Oral semaglutide reduces CV risk in T2D patients

15 Apr 2025

Clopidogrel outshines aspirin for secondary prevention in high-risk PCI patients

11 Apr 2025 by

In the long-term maintenance period after percutaneous coronary intervention (PCI), monotherapy with clopidogrel appears to work better than aspirin at preventing major adverse cardiac and cerebrovascular events in Asian patients at high risk of recurrent ischaemic events, as shown in the open-label SMART-CHOICE 3 trial conducted in South Korea.

Clopidogrel outshines aspirin for secondary prevention in high-risk PCI patients

11 Apr 2025

Dapagliflozin after TAVI improves outcomes in elderly patients with aortic stenosis

10 Apr 2025 by

Elderly patients with aortic stenosis who received dapagliflozin after transcatheter aortic-valve implantation (TAVI) had better outcomes than those who did not receive the drug, according to the DapaTAVI* trial presented at ACC.25.

Dapagliflozin after TAVI improves outcomes in elderly patients with aortic stenosis

10 Apr 2025